If you have been reading about NR1D2 and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2026-05-25. Where a claim depends on a specific study, the study is described rather than over-claimed.
SR9009 is a synthetic small molecule studied as an agonist of REV-ERB nuclear receptors. REV-ERB alpha and REV-ERB beta help regulate circadian rhythms and metabolic gene expression. In laboratory research, SR9009 has been used to probe how these receptors affect skeletal muscle, liver, and adipose tissue. The compound was identified in academic drug-discovery work and is often described in scientific literature by its chemical name and research code. It is not an approved medicine, and human clinical data remain limited or absent.
SR9009 binds REV-ERB receptors and alters their repressive activity on target genes. This action can change transcription of genes involved in lipid handling, glucose metabolism, and mitochondrial function. In rodent studies, treated animals have shown changes in muscle oxidative capacity and exercise performance, though effects vary by dose, duration, and model. The precise molecular steps connecting receptor binding to whole-body outcomes are still an active area of investigation. Findings in animals do not automatically translate to humans.
Preclinical reports have linked SR9009 to improved endurance and altered energy expenditure in rodents. Such findings have prompted interest in whether REV-ERB activation can influence skeletal muscle metabolism. However, the reported effects depend on dose, route, and experimental model, and replication across laboratories is limited. Human trials have not established comparable outcomes, so claims about exercise performance remain speculative. The absence of controlled human data is a central limitation in interpreting these observations.
The mechanism of action involves binding to REV-ERB receptors and recruiting corepressor complexes, which represses target gene transcription. This contrasts with many nuclear receptor agonists that activate transcription. Downstream effects may include changes in autophagy, mitochondrial biogenesis, and lipid handling, but the precise pathways remain an active area of study. Whether these molecular events translate into meaningful physiological effects in humans is unresolved. Most evidence comes from cultured cells and rodent models rather than human participants.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic REV-ERB agonist | Small-molecule nuclear receptor ligand |
| Appearance | Off-white to pale yellow solid | Typical for research-grade powder |
| Solubility class | Soluble in DMSO; low water solubility | Common stock solutions use organic solvent |
| Typical stock solvent | Dimethyl sulfoxide | Used for laboratory assays |
| Common analytical method | HPLC with UV or mass detection | Used for identity and purity checks |
In laboratory settings, SR9009 is typically characterized by liquid chromatography–mass spectrometry (LC-MS) or high-performance liquid chromatography with ultraviolet detection (HPLC-UV). These methods can confirm identity and estimate purity, but they require reference standards for accurate quantification. Because SR9009 is not a licensed pharmaceutical, no harmonized pharmacopeial monograph exists. Laboratories often validate in-house methods for matrices such as plasma, urine, or cell culture media. Sample preparation may involve protein precipitation or liquid-liquid extraction before analysis.
Physicochemical behavior influences handling. SR9009 is described as a solid with limited aqueous solubility, so organic solvents such as dimethyl sulfoxide or ethanol are common in research stock solutions. Aqueous dilution can produce precipitates if the organic content is too low. Light, heat, and repeated freeze-thaw cycles may affect stability. Storage recommendations usually specify a desiccated freezer environment protected from light, but exact stability data depend on the formulation and matrix.
Detection in biological samples can be complicated by rapid metabolism and low circulating concentrations. Some studies report phase I and phase II metabolites, and analytical methods may need to target those species in addition to the parent compound. Immunoassays are not broadly available, so mass spectrometry remains the main confirmatory approach. For anti-doping testing, laboratories look for SR9009 and its metabolites using validated LC-MS methods. Open questions include how long metabolites remain detectable and how different routes of administration alter detection windows.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. These receptors help regulate circadian rhythms, lipid metabolism, and inflammatory gene expression. In cell and animal experiments, SR9009 alters transcription of clock-controlled genes and metabolic pathways. The compound is not a hormone and does not resemble classical steroid structures. Its activity depends on binding to the ligand-binding domain of REV-ERB, where it can modify corepressor recruitment.
Research interest in SR9009 grew from studies of circadian biology and metabolic disease. Preclinical reports describe effects on exercise capacity, muscle metabolism, and blood lipid levels in rodents, but these findings come from controlled laboratory settings. The compound has low oral bioavailability in animals, which limits systemic exposure after swallowing. Investigators often use injected routes in experiments to achieve measurable plasma concentrations. Human clinical data are sparse, no approved therapeutic product exists, and whether animal effects translate to humans remains an open question.
Regulatory and sporting contexts treat SR9009 as a prohibited substance in many elite competitions. Its presence on banned lists reflects concerns about performance enhancement and unknown long-term safety. Analytical chemists have developed methods to detect the parent compound and its metabolites in urine and blood. Literature discussions distinguish between in vitro potency, animal pharmacology, and anecdotal human reports. The latter are difficult to verify because products sold online may lack purity or contain different compounds.
Sponsors Boy and Girl Scout troops, Red Cross, various parish functions, church retreats, visits the sick and assists the needy, sponsors masses; and supports students studying theology and Catholic educational activities. Merged into the First Catholic Slovak Ladies Association in 2004. Knights of Columbus Knights of Peter Claver - Founded in 1909 by members of Most Pure Heart of Mary Catholic Church in Mobile, Alabama, as a Black Catholic fraternal order, as Blacks were barred from the Knights of Columbus due to their race. Among the founders were The Rev. John H. Dorsey (the second Black Catholic priest ordained in the US), many White priests, and three Black parishioners. Knights of St. John - Founded in 1879. Membership is open to "practical Catholic gentlemen" ages 16–55. Social membership available was also available, even to those over 55. In 1978 there were 7,144 members. The international structure is called the "Supreme Commandery", regional structures "Grand Commanderies", and local units are called "Commanderies". There were 172 Commanderies in 1978 including 27 in "West Africa", 5 in Togo, and 8 in Trinidad and Tobago. The order has a secret ritual but dropped password in April 1977 because it was time-consuming and had "no appreciable organizational value". The group appears in uniforms for Catholic ceremonies such as first communions Masses, and confirmations. The order has a sports program that sponsors golf and bowling. There is also a death benefit.
=== Other === It may be used in combination with other antibiotics to treat pneumonia and can be used to prevent infection before surgery, particularly heart, lung, or bone surgery. When used to treat endocarditis, in combination with other antibiotics or alone, the dose of flucloxacillin may need to exceed the usual dose.
The capping mixture interferes with the sulfur transfer reaction, which results in the extensive formation of the phosphate triester internucleosidic linkages in place of the desired PS triesters. Therefore, for the synthesis of OPS, it is advisable to conduct the sulfurization step prior to the capping step.
==== United Kingdom ==== In the United Kingdom, preparations containing only dextropropoxyphene were discontinued in 2004. In 2007, the Medicines and Healthcare products Regulatory Agency removed the licence for co-proxamol, also called distalgesic. From then on in the UK, co-proxamol is only available on a named patient basis, for long-term chronic pain and only to those who have already been prescribed this medicine. Its withdrawal from the UK market is a result of concerns relating to its toxicity in overdose (even small overdoses can be fatal), and dangerous reaction with alcohol. Recreational use in the UK is uncommon. Many patients have been prescribed alternative combinations of drugs as a replacement. The motivation for the withdrawal of co-proxamol was the reduction in suicides and a key part of the agency's justification of its decision was based upon studies showing co-proxamol was no more effective than paracetamol alone in pain management. The co-proxamol preparations available in the UK contained a subtherapeutic dose of paracetamol, 325 mg per tablet. Patients were warned not to take more than eight tablets in one day, a total dose of 2600 mg paracetamol per day. Despite this reduced level, patients were still at a high risk of overdose; coproxamol was second only to tricyclic antidepressants as the most common prescription drugs used in overdose. Following the reduction in prescribing in 2005–2007, prior to its complete withdrawal, the number of deaths associated with the drug dropped significantly.
Sources: en.wikipedia.org
The demand increase is attributed to millennial consumers, and some companies have introduced vegetarian friendly options or done away with isinglass use. A beer-fining agent that is suitable for vegetarians is Irish moss, a type of red algae containing the polymer chemical carrageenan. However, carrageenan-based products (used in both the boiling process and after fermentation) primarily reduce hazes caused by proteins, but isinglass is used at the end of the brewing process, after fermentation, to remove yeast. Since the two fining agents act differently (on different haze-forming particles), they are not interchangeable, and some beers use both. Isinglass finings are also used in the production of kosher wines, although for reasons of kashrut, they are not derived from the beluga sturgeon, because this fish is not kosher. Whether the use of a nonkosher isinglass renders a beverage nonkosher is a matter of debate in Jewish law. Rabbi Yehezkel Landau, in Noda B'Yehuda, first edition, Yore Deah 26, for example, permits such beverages. This is the position followed by many kashrut-observant Jews today. The similar-sounding names has resulted in confusion between isinglass and waterglass (sodium silicate), especially as both have been used to preserve eggs. A solution of isinglass was applied to eggs and allowed to dry, sealing their pores. Eggs were submerged in solutions of waterglass, and a gel of silicic acid formed, also sealing the pores of the eggshell.
Ajahn Brahm agrees, writing that the main purpose of dependent origination is to explain "how there can be rebirth without a soul" and "why there is suffering, and where suffering comes to an end." Brahm cites the definitions of the nidanas in the Vibhaṅgasutta (SN 12.2) which clearly indicate that birth and death is meant literally. According to Brahm,Paṭicca-samuppāda shows the empty process, empty of a soul that is, which flows within a life and overflows into another life. It also shows the forces at work in the process, which drive it this way and that, even exercising sway in a subsequent life. Dependent origination also reveals the answer to how kamma done in a previous life can affect a person in this life. Brahm argues that there are two parallel processes at work in dependent origination (which are really one process looked at from different angles), one is delusion and kamma leading to rebirth consciousness (nidanas # 1 – 3) and the other is craving and clinging leading to existence and rebirth (# 8 – 11). Brahm describes this as follows: "deluded kamma and craving produce the fuel which generates existence and rebirth (into that existence), thereby giving rise to the start of the stream of consciousness that is at the heart of the new life." Furthermore, dependent origination explains rebirth without appeal to an unchanging self or soul (atman). Paul Williams sees dependent origination as closely connected with the doctrine of not-self (anatman) which rejects the idea there is an unchanging essence that moves across lives.
One measure of how well a molecule fits a receptor is its binding affinity, which is inversely related to the dissociation constant Kd. A good fit corresponds with high affinity and low Kd. The final biological response (e.g. second messenger cascade, muscle-contraction), is only achieved after a significant number of receptors are activated. Affinity is a measure of the tendency of a ligand to bind to its receptor. Efficacy is the measure of the bound ligand to activate its receptor.
Sources: en.wikipedia.org
Raphael Samuel (26 December 1934 – 9 December 1996), Marxist; prolific author and historian of Hungarian Jewish ancestry, described by Stuart Hall as "one of the most outstanding, original intellectuals of his generation"; member of Communist Party Historians Group, alongside Christopher Hill, E.P. Thompson; founded the Partisan Coffee House in 1956 in Soho, London, as a meeting place for British New Left. Anne-Marie Sandler (December 15, 1925 – July 25, 2018), psychologist and psychoanalyst noted for her clinical observation of the relationship dynamic between blind infants and their mothers in a project spearheaded by Anna Freud. whilst majoring in psychology at the University of Geneva, was selected by Jean Piaget as research assistant in his project with UNESCO in Switzerland, which focused on the development of children's perception of homeland and foreignness; highly regarded for her scholarly work "Beyond Eight Months Anxiety," published in 1977, where she reconceptualised the stranger anxiety experienced by infants as a condition that is also present in her adult clients; president of the European Psychoanalytical Federation (EPF) and president of BPS in 1990; appeared on television discussion programme After Dark, alongside among others Clive Ponting, Colin Wallace, T. E. Utley and Peter Hain; held prominent positions in the Anna Freud Centre; also active in the International Psychoanalytical Association. Joseph J.
=== Intravenous fluids === In those with poor tissue perfusion, boluses of isotonic crystalloid solution should be given. In children with more than 10–20% TBSA (Total Body Surface Area) burns, and adults with more than 15% TBSA burns, formal fluid resuscitation and monitoring should follow. This should be begun pre-hospital if possible in those with burns greater than 25% TBSA. The Parkland formula can help determine the volume of intravenous fluids required over the first 24 hours. The formula is based on the affected individual's TBSA and weight. Half of the fluid is administered over the first 8 hours, and the remainder over the following 16 hours. The time is calculated from when the burn occurred, and not from the time that fluid resuscitation began. Children require additional maintenance fluid that includes glucose. Additionally, those with inhalation injuries require more fluid. While inadequate fluid resuscitation may cause problems, over-resuscitation can also be detrimental. The formulas are only a guide, with infusions ideally tailored to a urinary output of >30 mL/h in adults or >1mL/kg in children and mean arterial pressure greater than 60 mmHg. While lactated Ringer's solution is often used, there is no evidence that it is superior to normal saline. Crystalloid fluids appear just as good as colloid fluids, and as colloids are more expensive they are not recommended. Blood transfusions are rarely required. They are typically only recommended when the hemoglobin level falls below 60-80 g/L (6-8 g/dL) due to the associated risk of complications.
According to Bernardo Houssay, who wrote a well-cited biography of Vital Brazil in 1966, his contributions went further than herpetology:"Vital Brazil and his collaborators have studied several actions of the venoms, (such as) coagulant, anticoagulant, hemolytic, agglutinant, cytotoxic, proteolytic, etc. (...) The (animal) poisons contain numerous enzymes which have been isolated and studied with interest in all parts since they explain many of the symptoms and constitute interesting biochemical reagents, Vital Brazil studied also the ophiophagous serpents, such as the mussurana, the ophiophagous mammals, such as the skunk-like Conepatus chilensis and others, the ophiophagous birds and certain spiders. (...) His book, La défense contre l’ophidisme published in French in 1914, attained international repercussion with three editions."
Sources: en.wikipedia.org
SR9009 is a synthetic research compound that acts on REV-ERB nuclear receptors. It is not approved for human use and is sold only as a research chemical. Its effects have been studied mainly in cells and rodents.
It binds REV-ERB alpha and REV-ERB beta and changes the expression of genes tied to metabolism and circadian rhythm. These changes can affect mitochondria and energy use in animal models. The exact chain from receptor binding to physiological outcome is still being mapped.
No reliable human trials show that SR9009 improves athletic performance. Some rodent studies report endurance changes, but these results are not proof of human benefit. Its use in sport is prohibited, and quality and safety data are lacking.
It is a synthetic compound that acts as an agonist at REV-ERBα and REV-ERBβ. It is used mainly as a research chemical to study circadian and metabolic pathways. It is not approved for human therapeutic use.